LipoMedix Pharmaceuticals is a privately held development-stage company focused on an innovative, safe, and effective cancer therapy based on liposome delivery.

The companys lead product, Promitil, has demonstrated antitumor effects in tumor models that rival or outperform the effects of many standard forms of chemotherapy, such as cisplatin, irinotecan, gemcitabine, and doxorubicin, with less toxicity.